

CONTENTS

Foreword.....	V
Contents	IX
List of figures.....	XV
List of tables.....	XIX
1. Introduction.....	1
2. Overview of influenza infection models	3
2.1 Experimental modelling of influenza.....	3
2.1.1 Human and primate influenza	3
2.1.2 Swine influenza modelling.....	4
2.1.2.1 Characterisation of porcine influenza viruses	5
2.1.2.2 Experimental infections of pigs with the pandemic virus of 1918.....	6
2.1.2.3 Experimental infections of pigs with avian influenza viruses.....	6
2.1.2.4 ANP32A.....	8
2.1.2.5 Experimental infections of pigs with B, C, and D influenza viruses	8
2.1.2.6 Study of immunological responses	9
2.1.2.7 Studies on comparative pathology.....	10
2.1.2.8 Gene editing.....	10
2.1.2.9 Studies on influenza virus receptors in pigs	10
2.1.2.10 Studies on the efficacy of vaccines.....	10
2.1.2.11 Studies on antibody-dependent enhancement of disease.....	11
2.1.2.12 Risk of zoonotic transmission through experimental infection of pigs..	12
2.1.3 Horse influenza models.....	12
2.1.4 Canine influenza models	12
2.1.5 Avian influenza models.....	13
2.1.6 Other animal models of influenza	13
2.1.6.1 Ferrets	13
2.1.6.2 Mice	15
2.1.6.3 Guinea pigs	15

2.1.6.4 Syrian hamster.....	15
2.1.6.5 Cats.....	15
2.1.6.6 Cattle	16
2.1.7 Alternatives to animal models	16
2.2 Maternally-derived immunity.....	17
2.2.1 Types of placenta and consequences for maternal-fetal exchange.....	17
2.2.2 The ontogeny of the pig immune system	18
2.2.3 Transmission of maternal antibodies via colostrum.....	19
2.2.4 The neonatal Fc receptor	19
2.2.5 Protection by maternally-derived immunitY	20
2.2.6 Influenza virus transmission under maternal immunity	21
2.2.7 Interference of maternal immunity with vaccination	22
2.2.8 Vaccine-induced enhanced disease under maternal immunity.....	22
3. Aim of the work	25
3.1 Validation of influenza infection models and investigations on pathogenesis	25
3.2 Investigation of maternal immunity	26
4. Materials and Methods	27
4.1 Investigations on swine influenza pathogenesis.....	27
4.2 Investigation of maternal immunity	39
5. Results.....	41
5.1 Pathogenesis of swine influenza.....	41
5.1.1 Investigation of experimental infection models	42
<i>5.1.1.1 Comparative analysis of swine influenza infection models</i>	42
5.1.2 The infectious dose - the main contributor to disease severity	44
<i>5.1.2.1 Dose titration of influenza viruses by aerosol</i>	44
5.1.3 Investigation of the virulence influenza A viruses after high-dose aerosol nebulisation.....	47
<i>5.1.3.1 Comparative analysis of virulence of influenza A viruses in pigs</i>	47
<i>5.1.3.2 Reassortant viruses reveal a unique role of the neuraminidase for virulence</i>	52
<i>5.1.3.3 Evolution of pandemic (H1N1) 2009 viruses towards a lower level of virulence</i>	54

5.1.4 Validation of aerosol nebulisation	61
<i>5.1.4.1 Investigation of virus stability during nebulisation</i>	61
<i>5.1.4.2 Investigation of virus distribution in pig tissues after infection</i>	61
5.1.5 Macroscopic lung gross lesions	69
5.1.6 Application of the aerosol model for scientific investigations	76
<i>5.1.6.1 Investigation of protective effects of immunogenic components of field isolates of influenza A viruses</i>	76
5.2 Application of high-dose aerosol nebulization to investigate effects of maternally-derived immunity	97
5.2.1 maternal immunity and antibody response to immunisation	97
<i>5.2.1.1 Sows concentrate antibodies in their colostrum prior to birth</i>	97
<i>5.2.1.2 Maternally-derived immunity inhibits seroconversion</i>	99
<i>5.2.1.3 Other factors of maternally-derived immunity than antibodies determine maternally-derived immunity in long-terms</i>	100
<i>5.2.1.4 Maternally-derived immunity induced by H1_{pdm}N1 2009 virus</i>	104
<i>5.2.1.5 Severe disease and recovery</i>	107
<i>5.2.1.6 Investigation on piglets of an age of 2 weeks at infection</i>	109
<i>5.2.1.7 Investigation of piglets of an age of 4 weeks at infection</i>	113
6. General discussion	117
6.1 Swine influenza pathogenesis	117
6.1.1 Swine influenza infection models are linked by the infectious dose	118
6.1.2 Influenza A viruses differ in virulence at high-dose aerosol infection.....	121
6.1.2.1 Description of differences in virulence	121
6.1.2.2 Newly emerged H1N1 viruses move towards lower virulence	122
6.1.3 Differences in virulence are linked by the neuraminidase	123
6.1.4 Influence of immunological response to viral proteins on virulence.....	129
6.1.5 Host factors contribute to different outcomes of infection	136
6.1.6 The lung lesion – key to decipher pathogenesis	136
6.1.7 Initial infectious viral load, host adaptation of virus and individual as well as environmental factors determines severity of disease.....	142
6.1.8 Conclusions for the analysis of pandemics	144
6.1.9 Virus gene expression in cells outside of the respiratory tract	149

6.1.10 Investigation of antivirals (neuraminidase inhibitors) – reveals the high-dose pig model as an ideal method	157
6.1.11 Immunosuppressive treatment – prolongs viral shedding.....	157
6.2 Analysis of components of maternally-derived immunity	159
6.2.1 Maternal immunity and prevention of disease	160
6.2.2 Interactions of maternal immunity with antibody response to immunisation	161
6.2.3 Virus shedding in piglets with maternal immunity	163
7. Summary	167
8. Acknowledgements	173
References	XXI
Supplementary material	LIX
Supplement chapter 1 – Overview of viruses used	LIX
Supplement chapter 2 – Viusualisation of infection methods	LX
Supplement chapter 3 – Specificity of SABC staining	LXIV
Supplement chapter 4 – Intramuscular infection.....	LXV
Supplement chapter 5 – Comparison of influenza infection models.....	LXVII
Supplement chapter 6 – Indirect contact infection.....	LXIX
Supplement chapter 7 – Aerosol versus intratracheal	LXXI
Comparative analysis of high-dose respiratory infection models	LXXI
Supplement chapter 8 – Dose titration of influenza viruses.....	LXXV
Dose titration of pandemic H1N1 2009 virus by aerosol	LXXV
Dose titration of swine human-like H3N2 virus by aerosol	LXXXV
Dose titration of swine avian-like H1N1 virus by aerosol	LXXXVI
Dose titration of classical swine H1N1 virus by aerosol.....	LXXXVII
Dose titration of swine pandemic H1N2 2010 virus by aerosol.....	XC
Dose titration of swine pandemic H1N1 2014 virus by aerosol.....	XCIII
Supplement chapter 9 – Stability of nebulized viruses	XCVII
Supplement chapter 10 – Analysis of H1 _{pdm} N1 viruses differing in virulence	XCIX
Clinical data	XCIX
Replication kinetics of H1 _{pdm} N1 viruses in cell culture	CIV
Replication kinetics of H1 _{pdm} N1 viruses in MBCK cells	CIV

Replication kinetics of H1 _{pdm} N1 viruses in MDCK cells.....	CVI
Replication kinetics of H1 _{pdm} N1 viruses in A549 cells	CVIII
Replication in of H1 _{pdm} N1 viruses in Calu cells.....	CIX
Replication kinetics of H1 _{pdm} N1 viruses in airway epithelial cells	CIX
Genetic characterisation of influenza A viruses differing in virulence	CX
Supplement chapter 11 – Virulence of H1 _{av} N1 1C.1 and 1C.2 viruses	CXVIII
H1 _{av} N1 1C.1 viruses	CXX
Supplement chapter 12 – Investigation of clinical chemical parameters.....	CXXII
Supplement chapter 13 – Enhancement of lung pathology within an antigenic supergroup (H1 _{pdm} versus H1 _{av})	CXXVII
Supplement chapter 14 – Pyrogenic and virucidal effects of mineral oils	CXXXV
Supplement chapter 15 – Stressing the innate immunity.....	CXXXVII
Supplement chapter 16 – Testing the relationship between H1 _{pdm} N1 and H1 _{cl} N1 influenza viruses.....	CXLV
Supplement chapter 17 – Influenza and Lethality	CLI
Supplement chapter 18 – Infection of pigs of different age.....	CLIV
Supplement chapter 19 – Analysis immunogenic effects of viral proteins	CLX
Supplement chapter 20 – Maternal immunity	CLXXI
Supplement chapter 21 – Thoughts on influenza and vaccinations	CLXXVIII
Supplement chapter 22 – Scientific background of the author	CLXXXI
Abbreviations	CLXXXV